NeuroSense Therapeutics (NASDAQ:NRSN) Research Coverage Started at Roth Mkm

Roth Mkm started coverage on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research note released on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $3.00 target price on the stock.

A number of other equities analysts have also recently issued reports on NRSN. Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of NeuroSense Therapeutics in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Stock Performance

Shares of NeuroSense Therapeutics stock opened at $0.85 on Tuesday. NeuroSense Therapeutics has a one year low of $0.68 and a one year high of $2.60. The stock’s 50-day moving average is $0.93 and its 200 day moving average is $1.03.

Institutional Trading of NeuroSense Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP bought a new position in NeuroSense Therapeutics in the 3rd quarter worth about $26,000. Jane Street Group LLC purchased a new stake in shares of NeuroSense Therapeutics in the second quarter worth about $54,000. Yorkville Advisors Global LP purchased a new stake in shares of NeuroSense Therapeutics in the fourth quarter worth about $77,000. Finally, Squarepoint Ops LLC boosted its position in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares during the period. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.